Ignite Creation Date:
2025-12-24 @ 5:57 PM
Ignite Modification Date:
2026-01-01 @ 2:56 PM
Study NCT ID:
NCT03477968
Status:
TERMINATED
Last Update Posted:
2025-02-25
First Post:
2018-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
ThRombosis ExclUsion STudy
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020246', 'term': 'Venous Thrombosis'}, {'id': 'D011655', 'term': 'Pulmonary Embolism'}, {'id': 'D054556', 'term': 'Venous Thromboembolism'}], 'ancestors': [{'id': 'D013927', 'term': 'Thrombosis'}, {'id': 'D016769', 'term': 'Embolism and Thrombosis'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D004617', 'term': 'Embolism'}, {'id': 'D013923', 'term': 'Thromboembolism'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'nathalie.thuillier@stago.com', 'phone': '+33 146 882 167', 'title': 'Nathalie THUILLIER', 'organization': 'Diagnostica STAGO S.A.S'}, 'certainAgreement': {'otherDetails': 'All the informations regarding the PIs restrictions are specified in the study agreement for each study site.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'In the EU / US, this was a non-interventional study in which patients received standard of care, unrelated to study procedures. As such, safety was not evaluated in this study.', 'description': 'In the EU / US, this was a non-interventional study in which patients received standard of care, unrelated to study procedures. As such, safety was not evaluated in this study.', 'eventGroups': [{'id': 'EG000', 'title': 'Pulmonary Embolism (PE) Arm', 'description': 'Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 13th February 2020\n\nDDimer test: Measuring the level of DDimer in blood sample', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Deep Venous Thrombosis (DVT) Arm', 'description': 'Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment on going : 29th March 2020\n\nDDimer test: Measuring the level of DDimer in blood sample', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'VTE Exclusion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Pulmonary Embolism (PE)', 'description': 'Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 13th February 2020\n\nDDimer test: Measuring the level of DDimer in blood sample'}, {'id': 'OG001', 'title': 'Deep Venous Thrombosis (DVT)', 'description': 'Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 29th March 2023\n\nDDimer test: Measuring the level of DDimer in blood sample'}], 'timeFrame': 'Initially, we planned to enroll subjects suspected of PE/DVT to constitute a plasmabank, then perform testing of STA- Liatest D-Di XL for on this latter on 48 months. However due to plasmabank unstability, Stago decided to not perform the testing phase.', 'description': 'According to the ThRombosis ExclUsion STudy (TRUST) protocol, the primary objective of the study was to demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity.\n\nThe first step was to evaluate the stability of the plasmabank using VIDAS system. The preliminary results showed that the plasmabank was unusable with a high rate of unstable samples. Stago, decided to not use this plasmabank to assess the ability of STA® - Liatest® D-Di XL to safely exclude PE and DVT.', 'reportingStatus': 'POSTED', 'populationDescription': 'As described in the Protocol Section, the study was halted prematurely, therefore there is no Outcome Measure data.'}, {'type': 'SECONDARY', 'title': 'VTE Exclusion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Pulmonary Embolism (PE)', 'description': 'Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 13th February 2020\n\nDDimer test: Measuring the level of DDimer in blood sample'}, {'id': 'OG001', 'title': 'Deep Venous Thrombosis (DVT)', 'description': 'Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.'}], 'timeFrame': 'Initially, we planned to enroll subjects suspected of PE/DVT to constitute a plasmabank, then perform testing of STA- Liatest D-Di XL. Due to plasmabank unstability, Stago decided to not perform the testing phase for the STA-D-Di XL and future DDi assays.', 'description': 'According to the ThRombosis ExclUsion STudy (TRUST) protocol, the secondary objectives of the study were:\n\n1. To estimate additional STA® - Liatest® D-Di XL accuracy parameters, including specificity and positive predictive value (PPV)\n2. To constitute a plasmabank to be used for future studies with other DDi assays under development by Stago.\n\nThe first step was to evaluate the stability of the plasmabank using VIDAS system. The preliminary results showed that the plasmabank was unusable with a high rate of unstable samples. Stago, decided to not use this plasmabank to assess the ability of STA® - Liatest® D-Di XL to safely exclude PE and DVT and to not use this plasmabank for future studies with other DDi assays under development by Stago.', 'reportingStatus': 'POSTED', 'populationDescription': 'As described in the Protocol Section, the study was halted prematurely, therefore there is no Outcome Measure data.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Pulmonary Embolism (PE)', 'description': 'Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 13th February 2020\n\nDDimer test: Measuring the level of DDimer in blood sample'}, {'id': 'FG001', 'title': 'Deep Venous Thrombosis (DVT)', 'description': 'Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3584'}, {'groupId': 'FG001', 'numSubjects': '2351'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2778'}, {'groupId': 'FG001', 'numSubjects': '1622'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '806'}, {'groupId': 'FG001', 'numSubjects': '729'}]}]}], 'preAssignmentDetails': 'As STA® - Liatest® D-Di XL was not available for testing before the end of the collection, it was not possible to anticipate the number of samples that might be lost during thawing due to stability. We decided to apply a 15% increase to the number of positives. Taking into account the decision to enroll N = 115 evaluable reference-positive subjects for each indication, sample size had to be recalculated. At study end, a total of 3,584 PE and 2,351 DVT subjects had been enrolled.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '2778', 'groupId': 'BG000'}, {'value': '1622', 'groupId': 'BG001'}, {'value': '4400', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Pulmonary Embolism (PE)', 'description': 'Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 13th February 2020\n\nDDimer test: Measuring the level of DDimer in blood sample'}, {'id': 'BG001', 'title': 'Deep Venous Thrombosis (DVT)', 'description': 'Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 29th March 2023\n\nDDimer test: Measuring the level of DDimer in blood sample'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'title': 'Pulmonary Embolism (PE) Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2778', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2778', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '45.8', 'spread': '15.2', 'groupId': 'BG000'}, {'value': '45.8', 'spread': '15.2', 'groupId': 'BG002'}]}]}, {'title': 'Deep Venous Thrombosis (DVT) Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '1622', 'groupId': 'BG001'}, {'value': '1622', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '51.9', 'spread': '14.7', 'groupId': 'BG001'}, {'value': '51.9', 'spread': '14.7', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'The primary aim of this trial was to demonstrate the ability of STA® - Liatest® D-Di XL to exclude PE and DVT in out patients with low or moderate clinical PreTest Probability for each indication separetely. In addition, during the study the enrolment in the DVT and PE arms was monitored separetely to achieve the desired sample size for each indication. Hence, this study is considered as single trial with two separate arms, the data as age were calculated only for each arm and not in total.'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '2778', 'groupId': 'BG000'}, {'value': '1622', 'groupId': 'BG001'}, {'value': '4400', 'groupId': 'BG002'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '1675', 'groupId': 'BG000'}, {'value': '994', 'groupId': 'BG001'}, {'value': '2669', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '1103', 'groupId': 'BG000'}, {'value': '628', 'groupId': 'BG001'}, {'value': '1731', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race and Ethnicity Not Collected', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'populationDescription': 'Race and Ethnicity were not collected from any participant.'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-08-24', 'size': 925701, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2024-09-03T10:45', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Plasma samples'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 5935}, 'patientRegistry': False}, 'statusModule': {'whyStopped': 'Due to the unstability of samples included in the plasmabank using the reference method: VIDAS system, Stago decided to not use the plasmabank to assess the pre-specified primary objective. Therefore, this study was halted prematurely.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2018-06-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-02', 'completionDateStruct': {'date': '2024-09-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-03', 'studyFirstSubmitDate': '2018-03-20', 'resultsFirstSubmitDate': '2024-09-05', 'studyFirstSubmitQcDate': '2018-03-20', 'lastUpdatePostDateStruct': {'date': '2025-02-25', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-12-06', 'studyFirstPostDateStruct': {'date': '2018-03-27', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-01-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-03-29', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'VTE Exclusion', 'timeFrame': 'Initially, we planned to enroll subjects suspected of PE/DVT to constitute a plasmabank, then perform testing of STA- Liatest D-Di XL for on this latter on 48 months. However due to plasmabank unstability, Stago decided to not perform the testing phase.', 'description': 'According to the ThRombosis ExclUsion STudy (TRUST) protocol, the primary objective of the study was to demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity.\n\nThe first step was to evaluate the stability of the plasmabank using VIDAS system. The preliminary results showed that the plasmabank was unusable with a high rate of unstable samples. Stago, decided to not use this plasmabank to assess the ability of STA® - Liatest® D-Di XL to safely exclude PE and DVT.'}], 'secondaryOutcomes': [{'measure': 'VTE Exclusion', 'timeFrame': 'Initially, we planned to enroll subjects suspected of PE/DVT to constitute a plasmabank, then perform testing of STA- Liatest D-Di XL. Due to plasmabank unstability, Stago decided to not perform the testing phase for the STA-D-Di XL and future DDi assays.', 'description': 'According to the ThRombosis ExclUsion STudy (TRUST) protocol, the secondary objectives of the study were:\n\n1. To estimate additional STA® - Liatest® D-Di XL accuracy parameters, including specificity and positive predictive value (PPV)\n2. To constitute a plasmabank to be used for future studies with other DDi assays under development by Stago.\n\nThe first step was to evaluate the stability of the plasmabank using VIDAS system. The preliminary results showed that the plasmabank was unusable with a high rate of unstable samples. Stago, decided to not use this plasmabank to assess the ability of STA® - Liatest® D-Di XL to safely exclude PE and DVT and to not use this plasmabank for future studies with other DDi assays under development by Stago.'}]}, 'oversightModule': {'isUsExport': False, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Deep Venous Thromboses', 'Pulmonary Embolism', 'Venous Thromboembolism']}, 'descriptionModule': {'briefSummary': 'Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative Predictive Value (NPV) and sensitivity.\n\nSecondary objectives:\n\n1. To estimate additional STA® - Liatest® D-Di XL accuracy parameters, including specificity and positive predictive value (PPV)\n2. To constitute a plasma bank to be used for future studies with other DDi assays under development by Stago.', 'detailedDescription': 'The study population will be selected from prospective, consecutive ambulatory outpatients suspected of having venous thromboembolism. Patients will be diagnosed for VTE (PE or DVT) based on local standard of care. Samples will be collected (additional blood draw or additional volume during blood draw) for future testing with new D-Dimer assay.\n\nIn case of Low/Moderate PTP score and negative VTE diagnosis, patients will be followed for 3 months to evaluate potential development of deep venous thrombosis and/or pulmonary embolism.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '79 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'The study population will be recruited from prospective, consecutive, ambulatory outpatients (presenting at the emergency unit or outpatient clinic) suspected of having VTE. Patients with DVT and PE will be analyzed as separate groups.', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Patient is \\< 80 years old.\n2. Patient presents at least one of these symptoms indicative of proximal DVT or PE:\n\n * symptoms for proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling, and /or edema,\n * symptoms for PE: hemoptysis, lung related chest pain, dyspnea.\n3. Patient provides written informed consent to participate in the study\n4. Patient is willing to comply with specified follow-up evaluation at 3 months and can be contacted by telephone.\n\nExclusion Criteria:\n\n1. Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as:\n\n * Fibrinolytic therapy within the previous seven (7) days,\n * Disseminated intravascular coagulation\n * Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month,\n * Deep hematoma diagnosed by imaging techniques within the previous one (1) month,\n * Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment),\n * Sepsis, severe infections, pneumonia within the previous 1 month,\n * Known liver cirrhosis,\n * Pregnancy or having delivered within the previous 1 month,\n * Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV),\n * Sickle cell disease,\n2. Patients presenting with a suspect thrombotic event related to catheter implantation\n3. Ongoing therapeutic anticoagulants (curative and preventive regimen) started twenty four (24) hours or more before blood draw (except aspirin and platelet inhibitors)\n4. Previous anticoagulant therapy stopped less than three (3) months before blood draw (except aspirin and platelet inhibitors)\n5. Patients with previous DVT/PE occurred less than three (3) months from screening.\n6. Suspect thrombotic events in other locations at screening, including distal to the knee and upper extremity DVT (based on standard of care examinations)\n7. Patients with known tissue plasminogen activator (tPA) deficiency\n8. Patient participating or who has participated within one month of enrolment in another investigational study\n9. Major co-morbid condition(s) or other reasons that could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study."}, 'identificationModule': {'nctId': 'NCT03477968', 'acronym': 'TRUST', 'briefTitle': 'ThRombosis ExclUsion STudy', 'organization': {'class': 'INDUSTRY', 'fullName': 'Diagnostica Stago'}, 'officialTitle': 'ThRombosis ExclUsion STudy', 'orgStudyIdInfo': {'id': 'TRUST study'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Pulmonary Embolism (PE)', 'description': 'Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 13th February 2020', 'interventionNames': ['Diagnostic Test: DDimer test']}, {'label': 'Deep Venous Thrombosis (DVT)', 'description': 'Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.\n\nEnrolment completed for this group : 29th March 2023', 'interventionNames': ['Diagnostic Test: DDimer test']}], 'interventions': [{'name': 'DDimer test', 'type': 'DIAGNOSTIC_TEST', 'description': 'Measuring the level of DDimer in blood sample', 'armGroupLabels': ['Deep Venous Thrombosis (DVT)', 'Pulmonary Embolism (PE)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Yale New Haven Hospital', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '46202', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Indiana University Health', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '42718', 'city': 'Campbellsville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Taylor regional Hospital', 'geoPoint': {'lat': 37.3434, 'lon': -85.34191}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Washington University', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Duke Hemostasis and Thrombosis Research Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Ohio State University', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '18103', 'city': 'Allentown', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Lehigh Hospital', 'geoPoint': {'lat': 40.60843, 'lon': -75.49018}}, {'zip': '18015', 'city': 'Bethlehem', 'state': 'Pennsylvania', 'country': 'United States', 'facility': "St Luke's University Health Network", 'geoPoint': {'lat': 40.62593, 'lon': -75.37046}}, {'zip': '19107', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Jefferson University Hospital', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'UT Southwestern', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'city': 'Brussels', 'country': 'Belgium', 'facility': 'Cliniques Universitaires St Luc', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Angers', 'country': 'France', 'facility': 'CHU', 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'city': 'Dijon', 'country': 'France', 'facility': 'CHU', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'city': 'Grenoble', 'country': 'France', 'facility': 'CHU', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'city': 'Rouen', 'country': 'France', 'facility': 'CHU', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'city': 'Bologna', 'country': 'Italy', 'facility': 'University Hospital S. Orsola-Mapighi', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Universitario Virgen del Rocio', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'Soria', 'country': 'Spain', 'facility': 'General Hospital', 'geoPoint': {'lat': 41.76401, 'lon': -2.46883}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Diagnostica Stago', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}